About Alpha-sarcoglycan
Alpha-sarcoglycan (SGCA) is a protein
from Homo sapiens identified by UniProt accession
Q16586, 387 residues long.
MolForge cross-references it against 0 known binders and
286 disease associations.
Target properties
| Protein name | Alpha-sarcoglycan |
| UniProt accession | Q16586 |
| Gene | SGCA |
| Organism | Homo sapiens |
| Length | 387 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (286)
Diseases linked to this target (Open Targets).
- autosomal recessive limb-girdle muscular dystrophy type 2D · score 0.84
- limb-girdle muscular dystrophy · score 0.67
- autosomal recessive limb-girdle muscular dystrophy · score 0.62
- Abnormality of the musculature · score 0.51
- sarcoglycanopathy · score 0.50
- heel bone mineral density · score 0.36
- genetic disorder · score 0.19
- cortical surface area measurement · score 0.13
- qualitative or quantitative defects of alpha-sarcoglycan · score 0.12
- cup-to-disc ratio measurement · score 0.12
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q16586-F1 | alphafold | PREDICTED | 80.02 | — |
Amino-acid sequence (387 residues)
MAETLFWTPL LVVLLAGLGD TEAQQTTLHP LVGRVFVHTL DHETFLSLPE HVAVPPAVHI TYHAHLQGHP DLPRWLRYTQ RSPHHPGFLY GSATPEDRGL QVIEVTAYNR DSFDTTRQRL VLEIGDPEGP LLPYQAEFLV RSHDAEEVLP STPASRFLSA LGGLWEPGEL QLLNVTSALD RGGRVPLPIE GRKEGVYIKV GSASPFSTCL KMVASPDSHA RCAQGQPPLL SCYDTLAPHF RVDWCNVTLV DKSVPEPADE VPTPGDGILE HDPFFCPPTE APDRDFLVDA LVTLLVPLLV ALLLTLLLAY VMCCRREGRL KRDLATSDIQ MVHHCTIHGN TEELRQMAAS REVPRPLSTL PMFNVHTGER LPPRVDSAQV PLILDQH
Explore Alpha-sarcoglycan with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets